PCSK9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease. (Q39453691)

From Wikidata

Jump to navigation Jump to search

scientific article

Sprache	Label	Description	Also known as
Englisch	PCSK9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28736830%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

PCSK9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28736830%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

atherosclerosis

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28736830%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28736830%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

2

object named as

Gerald F Watts

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

author name string

Michael M Page

1

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

publication date

30 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28736830%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28736830%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28736830%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28736830%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

270-282

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28736830%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

A receptor-mediated pathway for cholesterol homeostasis

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

The LDL receptor

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

The role of early LDL lowering to prevent the onset of atherosclerotic disease

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Sorting an LDL receptor with bound PCSK9 to intracellular degradation

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Genetic and metabolic determinants of plasma PCSK9 levels

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Self-association of human PCSK9 correlates with its LDLR-degrading activity

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Unravelling the functional significance of PCSK9.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin type 9.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Genetic identification of familial hypercholesterolemia within a single U.S. health care system

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Lipoprotein apheresis and new therapies for severe familial hypercholesterolemia in adults and children

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Liver transplantation for the treatment of homozygous familial hypercholesterolaemia in an era of emerging lipid-lowering therapies.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Lipoprotein(a) as a therapeutic target in cardiovascular disease

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Lipoprotein(a) as a cardiovascular risk factor: current status

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Lipoprotein(a): an important cardiovascular risk factor and a clinical conundrum.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Genome- and exome-wide association study of serum lipoprotein (a) in the Jackson Heart Study.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Genetically elevated lipoprotein(a) and increased risk of myocardial infarction

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Lipoprotein(a) for risk assessment in patients with established coronary artery disease

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a)

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Latest developments in the treatment of lipoprotein (a).

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Effects of extended-release niacin with laropiprant in high-risk patients

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Statin myopathy: the fly in the ointment for the prevention of cardiovascular disease in the 21st century?

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Narrative review: statin-related myopathy

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016).

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Risks associated with statin therapy: a systematic overview of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Interpretation of the evidence for the efficacy and safety of statin therapy

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Myotoxic reactions to lipid-lowering therapy are associated with altered oxidation of fatty acids

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Role of Nutraceuticals in Hypolipidemic Therapy

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Lipid-modifying effects of nutraceuticals: An evidence-based approach

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Effect of Bile Acid Sequestrants on the Risk of Cardiovascular Events: A Mendelian Randomization Analysis

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

A Highly Durable RNAi Therapeutic Inhibitor of PCSK9.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised con

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Efficacy and Safety of Alirocumab in Japanese Patients With Heterozygous Familial Hypercholesterolemia or at High Cardiovascular Risk With Hypercholesterolemia Not Adequately Controlled With Statins　- ODYSSEY JAPAN Randomized Controlled Trial.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) Ex Vivo: An Effect Blunted by Alirocumab.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Identification of megalin/gp330 as a receptor for lipoprotein(a) in vitro

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Galactose-specific asialoglycoprotein receptor is involved in lipoprotein (a) catabolism

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Recycling of Apolipoprotein(a) After PlgRKT-Mediated Endocytosis of Lipoprotein(a).

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: Rationale and design of the ODYSSEY ESCAPE trial.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Determining When to Add Nonstatin Therapy: A Quantitative Approach

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Safety profile of subjects treated to very low low-density lipoprotein cholesterol levels (<30 mg/dl) with rosuvastatin 20 mg daily (from JUPITER).

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin bac

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

PCSK9 inhibitor access barriers-issues and recommendations: Improving the access process for patients, clinicians and payers.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized Phase 3 trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13070

21 January 2018

Identifiers

10.1111/DOM.13070

1 reference

https://api.fatcat.wiki/v0/release/tvssszztgzhi7ax5x6bmiymo2m

30 July 2022

based on heuristic

mapped directly with Wikidata item

release_tvssszztgzhi7ax5x6bmiymo2m

1 reference

https://api.fatcat.wiki/v0/release/tvssszztgzhi7ax5x6bmiymo2m

30 July 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

https://api.fatcat.wiki/v0/release/tvssszztgzhi7ax5x6bmiymo2m

30 July 2022

based on heuristic

mapped directly with Wikidata item

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39453691&oldid=1801639352"